"Anything FDA does to promote transparency is good for us," said Lynda Dee, a patient representative for the FDA's Antiviral Drugs Advisory Committee and a founding member of the AIDS Treatment Activist Coalition in Baltimore. "This will go far in helping people who need these new treatments."
Read more in Health Day - U.S. News and World Report, August 12, 2009.
1 comments:
The FDA also publshed its rule on charging for drugs in a clinical trial and that has received scant attntion
Post a Comment